Rise of GLP-1 Agonists & Their Side Effects
Amid surging prescriptions for GLP-1 receptor agonists, clinicians review cutting-edge cardiovascular outcomes and periprocedural strategies while synthesizing landmark trials on MACE, glycemic control, and weight loss. Understand benefits, recognize adverse effects that shape inpatient decisions, and demonstrate practical protocols that provide safer, evidence-based care across diabetes and obesity.
Availability
On-Demand
Expires on Apr 30, 2027
Cost
Member: $0.00
Non-Member: $55.00
Credit Offered
0.75 CME Credit
0.75 ABIM-MOC Point
0.75 Participation Credit
  • Overview
  • Faculty
  • Accreditation
  • Recommended
Learning Objectives
After completing this activity, learners should be able to:
  1. Review the latest cardiovascular outcomes data in the management of type 2 diabetes and obesity.
  2. Understand the clinical benefits of GLP-1 RA for type 2 diabetes, weight loss, and obesity.
  3. Review the common side effects of GLP-1 RA.
  4. Recognize common periprocedural and inpatient management considerations.
Faculty
  • Lily Ackermann, ScM, MD, FACS, SFHM
Faculty Disclosures (PDF)

Faculty Disclosures
The individuals in control of content for this activity have no relevant relationships with ACCME-defined ineligible companies to disclose unless listed here. Any relevant relationships were mitigated prior to the start of this activity.

 
Accreditation Statement
The Society of Hospital Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Credit Statement
The Society of Hospital Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

IOS App Download Powered By